Immunocore Holdings plc (NASDAQ:IMCR) to Post Q1 2024 Earnings of ($0.49) Per Share, Leerink Partnrs Forecasts

Immunocore Holdings plc (NASDAQ:IMCR) – Investment analysts at Leerink Partnrs issued their Q1 2024 earnings estimates for Immunocore in a report issued on Monday, April 29th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.49) per share for the quarter. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.55) per share. Leerink Partnrs also issued estimates for Immunocore’s Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.58) EPS and FY2025 earnings at ($2.14) EPS.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.12). The business had revenue of $70.16 million for the quarter, compared to analysts’ expectations of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The firm’s quarterly revenue was up 22.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.63) EPS.

Other research analysts have also issued reports about the company. Guggenheim reissued a “buy” rating and issued a $92.00 price target on shares of Immunocore in a research report on Tuesday, April 23rd. SVB Leerink initiated coverage on shares of Immunocore in a report on Monday, April 29th. They set an “outperform” rating and a $74.00 target price for the company. Needham & Company LLC restated a “buy” rating and issued a $81.00 target price on shares of Immunocore in a research note on Thursday, April 11th. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Immunocore in a research report on Wednesday, March 6th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Immunocore from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $80.92.

Immunocore Trading Up 1.3 %

IMCR opened at $60.23 on Thursday. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. The company has a market capitalization of $3.00 billion, a P/E ratio of -51.92 and a beta of 0.92. The stock’s fifty day moving average is $61.48 and its two-hundred day moving average is $60.93. Immunocore has a 52 week low of $42.21 and a 52 week high of $76.98.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its position in Immunocore by 103.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock worth $43,000 after buying an additional 426 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company’s stock valued at $181,000 after buying an additional 674 shares during the period. JGP Global Gestao de Recursos Ltda. purchased a new position in Immunocore in the fourth quarter worth approximately $230,000. NEOS Investment Management LLC acquired a new position in Immunocore during the 4th quarter worth approximately $262,000. Finally, Oppenheimer Asset Management Inc. lifted its position in shares of Immunocore by 26.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 7,491 shares of the company’s stock worth $389,000 after purchasing an additional 1,572 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.